EMJ Nephrology最新文献_第3页

Proteinuria as a Surrogate Endpoint for Disease Progression in IgA Nephropathy: Predicting Long-Term Treatment Effects of Sparsentan 蛋白尿作为IgA肾病疾病进展的替代终点:预测斯帕森坦的长期治疗效果

EMJ Nephrology Pub Date : 2023-07-27 DOI: 10.33590/emjnephrol/10308654

J. George

{"title":"Proteinuria as a Surrogate Endpoint for Disease Progression in IgA Nephropathy: Predicting Long-Term Treatment Effects of Sparsentan","authors":"J. George","doi":"10.33590/emjnephrol/10308654","DOIUrl":"https://doi.org/10.33590/emjnephrol/10308654","url":null,"abstract":"IgA nephropathy (IgAN) is a rare, life-limiting disease for which there is significant unmet need. Until recently, drug development for IgAN had been impeded by the requirement for large-scale, long-term clinical trials to measure clinical outcomes. However, the recent establishment of ‘reduction in proteinuria’ as a surrogate endpoint to predict clinical outcomes in IgAN, as a basis for accelerated drug approval, has transformed the field. At the 60th European Renal Association (ERA) Congress in June 2023, two oral poster presentations focused on the use of early reduction in proteinuria as an endpoint for clinical studies in IgAN. Alex Mercer, Consultant in Clinical Drug Development at JAMCO Pharma Consulting in Stockholm, Sweden, presented data estimating the long-term clinical outcome of reductions in proteinuria (clinically meaningful extensions in time to kidney failure or death), which could help predict the future protective effect of any new intervention on kidney function. Following this, Jonathan Barratt, Mayer Professor of Renal Medicine at the University of Leicester, and Honorary Consultant Nephrologist at Leicester General Hospital, UK, described findings from the prespecified interim analysis of the Phase III PROTECT study of sparsentan (a novel dual endothelin angiotensin receptor antagonist) in IgAN, which included reduction in proteinuria as a primary endpoint. In patients with IgAN at high risk of disease progression, sparsentan produced a rapid and significant reduction in proteinuria of a level that, according to the study data presented by Mercer, would correspond to a substantially lowered risk of kidney failure or death. Long-term data to confirm this predicted clinical outcome on disease progression are anticipated.","PeriodicalId":348431,"journal":{"name":"EMJ Nephrology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122330973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interview: Catherine Quinlan 采访:凯瑟琳·昆兰

EMJ Nephrology Pub Date : 2023-07-27 DOI: 10.33590/emjnephrol/10300030

引用次数: 0

Recent Advances in Targeting Complement in Glomerular Disease 靶向补体治疗肾小球疾病的最新进展

EMJ Nephrology Pub Date : 2023-07-27 DOI: 10.33590/emjnephrol/10303666

M. Salvadori

{"title":"Recent Advances in Targeting Complement in Glomerular Disease","authors":"M. Salvadori","doi":"10.33590/emjnephrol/10303666","DOIUrl":"https://doi.org/10.33590/emjnephrol/10303666","url":null,"abstract":"Several diseases are related to complement involvement. In particular, its role is essential for the pathogenesis of several renal disease. On the other hand, the complement role may also be protective, and this possibility should be well known when managing complement inhibitors.\u0000\u0000Complement inhibitors are relatively newly discovered therapies that are essential in some diseases, and in others improve the efficacy of the already known therapeutic measures that represent the standard of care.\u0000\u0000In the case of glomerular diseases, complement plays a role in almost all diseases. In some diseases, complement abnormalities represent the prevailing factor in the pathogenesis. In such diseases, complement inhibition represents an essential therapy. In other diseases, complement plays an important role, but other factors are involved in the pathogenesis. Clearly, in these diseases, complement inhibition represents a therapy that could be added to the standard of care therapy, according to the physician’s judgement. Examples of these diseases are lupus nephritis, thrombotic microangiopathy when associated to some cases of lupus nephritis, and IgA nephropathy. The latter is one of the first primary glomerulonephritides in which a relevant role of complement is documented. These three diseases are the object of this brief review. Particular concern should be given to ongoing clinical trials. Indeed, many of these anti-complement therapies are still in different phases of clinical trials. Finally, particular concern must be ascribed to the problem of associating these emerging therapies to already existing and proven treatments.","PeriodicalId":348431,"journal":{"name":"EMJ Nephrology","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130340842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary Acute Kidney Injury Management 当代急性肾损伤管理

EMJ Nephrology Pub Date : 2023-07-27 DOI: 10.33590/emjnephrol/10302800

E. Koutsouki

引用次数: 0

Intrahepatic Splenosis in a Patient with Autoimmune Hepatitis with No History of Splenectomy or Abdominal Trauma 无脾切除术或腹部创伤史的自身免疫性肝炎患者肝内脾亢1例

EMJ Nephrology Pub Date : 2023-07-23 DOI: 10.33590/emjhepatol/10307663

Keiya Aono, Takahiro Suzuki, Masaoki Hattori, M. Yoshihara

引用次数: 0

Steroid-Dependent Nephrotic Syndrome in a Child After an Allogeneic Bone Marrow Transplant: A Case Report 异基因骨髓移植后儿童类固醇依赖性肾病综合征1例报告

EMJ Nephrology Pub Date : 2023-07-19 DOI: 10.33590/emjnephrol/10301955

Uzma Zahid, M. Mahmood